BACKGROUND: The deregulation of several transcription factors contribute to the aggressive course of mantle cell lymphoma. This study focuses on survival signals emanating from the tumor environment and involving the signal transducer and activator of transcription (STAT) 3 through cytokines or antigen recognition. DESIGN AND METHODS: Primary mantle cell lymphoma cells were isolated from 20 leukemic patients. The phosphorylation status of STAT3 was evaluated by immunoblottting and immunofluorescence, the levels of cytokine secretion by enzyme-linked immunosorbent assay and the cell survival signals by apoptosis and cell viability assays. RESULTS: STAT3 was constitutively phosphorylated in the Jeko-1 mantle cell lymphoma cell line and in 14 out of 20 (70%) cases of leukemic mantle cell lymphoma as the result of an autocrine secretion of interleukin-6 and/or interleukin-10. In addition, B-cell receptor engagement resulted in an increase of both in vitro cell survival and STAT3 phosphorylation in primary mantle cell lymphoma cells. Inhibition of the Janus-activated kinase/STAT3 pathway increased spontaneous apoptosis and suppressed B-cell receptor-induced cell survival in all cases analyzed. The impact of in vitro exposure to the proteasome inhibitor bortezomib was next evaluated in primary mantle cell lymphoma cells. Bortezomib induced apoptosis and a decrease of both interleukin-6/interleukin-10 secretion and STAT3 phosphorylation. In addition, bortezomib inhibited B-cell receptor-triggered STAT3 phosphorylation and cell survival. CONCLUSIONS: We demonstrated that STAT3 was activated in primary mantle cell lymphoma cells either constitutively through a cytokine autocrine loop or in response to B-cell receptor engagement, both processes leading to a survival signal inhibited by bortezomib. STAT3 appears, therefore, to play a pivotal role in mantle cell lymphoma and represents a promising therapeutic target.
BACKGROUND: The deregulation of several transcription factors contribute to the aggressive course of mantle cell lymphoma. This study focuses on survival signals emanating from the tumor environment and involving the signal transducer and activator of transcription (STAT) 3 through cytokines or antigen recognition. DESIGN AND METHODS: Primary mantle cell lymphoma cells were isolated from 20 leukemicpatients. The phosphorylation status of STAT3 was evaluated by immunoblottting and immunofluorescence, the levels of cytokine secretion by enzyme-linked immunosorbent assay and the cell survival signals by apoptosis and cell viability assays. RESULTS:STAT3 was constitutively phosphorylated in the Jeko-1 mantle cell lymphoma cell line and in 14 out of 20 (70%) cases of leukemic mantle cell lymphoma as the result of an autocrine secretion of interleukin-6 and/or interleukin-10. In addition, B-cell receptor engagement resulted in an increase of both in vitro cell survival and STAT3 phosphorylation in primary mantle cell lymphoma cells. Inhibition of the Janus-activated kinase/STAT3 pathway increased spontaneous apoptosis and suppressed B-cell receptor-induced cell survival in all cases analyzed. The impact of in vitro exposure to the proteasome inhibitor bortezomib was next evaluated in primary mantle cell lymphoma cells. Bortezomib induced apoptosis and a decrease of both interleukin-6/interleukin-10 secretion and STAT3 phosphorylation. In addition, bortezomib inhibited B-cell receptor-triggered STAT3 phosphorylation and cell survival. CONCLUSIONS: We demonstrated that STAT3 was activated in primary mantle cell lymphoma cells either constitutively through a cytokine autocrine loop or in response to B-cell receptor engagement, both processes leading to a survival signal inhibited by bortezomib. STAT3 appears, therefore, to play a pivotal role in mantle cell lymphoma and represents a promising therapeutic target.
Authors: Dirk Kienle; Alexander Kröber; Tiemo Katzenberger; German Ott; Elke Leupolt; Thomas F E Barth; Peter Möller; Axel Benner; Annett Habermann; Hans Konrad Müller-Hermelink; Martin Bentz; Peter Lichter; Hartmut Dōhner; Stephan Stilgenbauer Journal: Blood Date: 2003-07-03 Impact factor: 22.113
Authors: Mario I Vega; Sara Huerta-Yepaz; Hermes Garban; Ali Jazirehi; Christos Emmanouilides; Benjamin Bonavida Journal: Oncogene Date: 2004-04-29 Impact factor: 9.867
Authors: Nerea Martínez; Francisca I Camacho; Patrocinio Algara; Antonia Rodríguez; Ana Dopazo; Elena Ruíz-Ballesteros; Paloma Martín; Jose A Martínez-Climent; Javier García-Conde; Javier Menárguez; Fernando Solano; Manuela Mollejo; Miguel A Piris Journal: Cancer Res Date: 2003-12-01 Impact factor: 12.701
Authors: Stefano Casola; Kevin L Otipoby; Marat Alimzhanov; Sibille Humme; Nathalie Uyttersprot; Jeffery L Kutok; Michael C Carroll; Klaus Rajewsky Journal: Nat Immunol Date: 2004-02-01 Impact factor: 25.606
Authors: R Letestu; V Ugo; F Valensi; I Radford-Weiss; J Nataf; V Lévy; J G Gribben; X Troussard; F Ajchenbaum-Cymbalista Journal: Leukemia Date: 2004-05 Impact factor: 11.528
Authors: Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor Journal: Cancer Res Date: 2012-06-22 Impact factor: 12.701
Authors: Nasser K Yaghi; Jun Wei; Yuuri Hashimoto; Ling-Yuan Kong; Konrad Gabrusiewicz; Edjah K Nduom; Xiaoyang Ling; Neal Huang; Shouhao Zhou; Brittany C Parker Kerrigan; Jonathan M Levine; Virginia R Fajt; Gwendolyn Levine; Brian F Porter; Eric G Marcusson; Kiyoshi Tachikawa; Padmanabh Chivukula; David C Webb; Joseph E Payne; Amy B Heimberger Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Andrew J Cowan; Shani L Frayo; Oliver W Press; Maria C Palanca-Wessels; John M Pagel; Damian J Green; Ajay K Gopal Journal: Anticancer Drugs Date: 2015-10 Impact factor: 2.248